Apathetic Hyperthyroidism: The Diagnosis Hiding Behind a Slower Presentation
An 84-year-old man's family says he's just "slowing down," and his labs say he's profoundly hyperthyroid. The disagreement is how aggressively to treat a diagnosis whose biggest danger, in a heart his age, is the same one everyone almost missed.
Edmund V., an 84-year-old retired watchmaker, was brought in by his daughter for what she described as three months of "just not being himself" — less interested in his workbench, sleeping more, eating less, and losing weight she'd assumed was appetite decline that comes with age. He wasn't tremulous, wasn't anxious, and denied feeling hot; if anything, he seemed slowed down and withdrawn, which is exactly why the diagnosis wasn't on anyone's radar until routine labs, ordered to work up his weight loss, came back with a TSH too low to detect and a free T4 more than twice the upper limit of normal. His ECG in clinic showed new atrial fibrillation with a ventricular rate of 118, which nobody had caught because he hadn't reported palpitations — he says his heart "doesn't really race, it just feels off."
Apathetic hyperthyroidism — the presentation Lahey named in the 1930s and Trivalle and colleagues later quantified against younger thyrotoxic patients — describes exactly this pattern: lethargy, depression, weight loss, and cardiovascular findings substituting for the tremor, heat intolerance, and anxiety that make hyperthyroidism obvious in younger patients — and it isn't a diagnostic curiosity so much as a recognized reason older hyperthyroid patients are diagnosed later and arrive sicker than younger ones, often first through a cardiac complication like his new atrial fibrillation rather than through classic symptoms prompting the workup. His new arrhythmia is now the central complicating fact: an 84-year-old man's heart tolerates rapid biochemical correction of severe hyperthyroidism less predictably than a younger patient's does, and his atrial fibrillation itself carries its own independent, immediate stroke and hemodynamic risk that exists somewhat separately from how fast his thyroid numbers come down.
Deciding how fast to correct a diagnosis nobody caught early
I'd start methimazole at a standard, not reduced, dose and add a beta-blocker for rate control. His hyperthyroidism is severe and his atrial fibrillation is very likely a direct downstream consequence of it — correcting the thyrotoxicosis is itself the most direct way to address the arrhythmia's underlying driver, not a separate problem to solve after the thyroid is fixed.
I agree treating the thyrotoxicosis is central, but I wouldn't assume his atrial fibrillation will simply resolve once his labs normalize, and I wouldn't manage his rate control as an afterthought to the thyroid plan. He needs a real anticoagulation decision made now — his stroke risk exists today, independent of how quickly his TSH recovers — and beta-blocker dosing in an 84-year-old with unknown baseline cardiac function needs more caution than "add a beta-blocker" implies.
Framing his AFib as something that follows from treating the thyroid risks under-prioritizing a decision that has its own timeline and its own risk if delayed — a stroke doesn't wait for his free T4 to normalize.
Both are right, and I'd add one more piece neither has addressed: whatever functional decline brought him in over these three months needs its own assessment, not an assumption that it will simply reverse once his thyroid and rhythm are treated. Start the methimazole, make the anticoagulation decision today rather than deferring it, and start beta-blockade conservatively given his age and unknown baseline function — but also get a real functional and cognitive baseline now, so we can tell in follow-up whether "getting back to himself" is actually happening or whether something else was contributing to his decline that treating his thyroid alone won't fix.
Agreed: methimazole started today, anticoagulation decided today rather than deferred, and conservative beta-blocker dosing given his age and unknown cardiac baseline, alongside a formal functional and cognitive baseline assessment.
Not agreed: whether his atrial fibrillation should be expected to resolve once he's biochemically euthyroid, or whether it should be managed as a likely-permanent new diagnosis regardless of the thyroid outcome. The endocrinologist expects a real chance of spontaneous conversion once his thyroid normalizes, based on how directly thyrotoxicosis can precipitate AFib in older patients; the cardiologist would plan his anticoagulation and rate-control strategy as though it may be permanent, unwilling to build a plan around an expected reversal that isn't guaranteed.